Composition for preventing, alleviating, or treating inflammatory bowel disease, comprising cynomorium songaricum extract as active ingredient

Abstract

The present invention relates to a composition for preventing, alleviating, or treating inflammatory bowel disease, the composition comprising a Cynomorium songaricum extract as an active ingredient. In an animal model of inflammatory bowel disease induced by dextran sulfate sodium (DSS), the Cynomorium songaricum extract increases body weight reduced due to DSS and reduces increased colon weight, and in particular, a mixture of the Cynomorium songaricum extract and a Gleditsia sinensis sting extract more significantly reduces a disease activity index increased by DSS administration than the Cynomorium songaricum extract or the Gleditsia sinensis sting extract alone. Thus, the composition can be highly effectively used in health functional foods or medicines for preventing, alleviating, or treating inflammatory bowel disease.

Description

Composition for preventing, improving or treating inflammatory bowel disease containing an extract of the root of the plant as an active ingredient

[0001] The present invention relates to a composition for preventing, improving or treating inflammatory bowel disease, comprising a chain extract as an active ingredient.

[0002]

[0003] This work was carried out with the support of the Ministry of Science and ICT's major projects (Project Number: 2710087090).

[0004] Inflammatory bowel disease (IBD) includes ulcerative colitis, Crohn's disease, and Behcet's disease. It is known that inflammatory cell activation is a major cause of the disease, and treatment requires suppressing inflammatory cell activation with anti-inflammatory drugs and immunosuppressants. In other words, even for intestinal diseases, treatment methods should vary depending on the specific cause, and in the case of inflammatory bowel disease in particular, finding ways to suppress and alleviate inflammation-related symptoms is the most important factor in disease treatment. Persistent or inappropriate activation of the intestinal immune system plays a significant role in the pathophysiology of chronic mucosal inflammation, and in particular, it ultimately leads to mucosal destruction and ulceration through infiltration of neutrophils, macrophages, lymphocytes, and mast cells.

[0005] Inflammatory bowel disease (IBD), various inflammatory cytokines are secreted from the intestinal mucosa. TNF-α is highly expressed in the colonic lumen and colonic epithelial cells of patients with ulcerative colitis, and recent studies have shown that TNF-α plays a significant role in the pathogenesis of ulcerative colitis. The anti-TNF-α antibody, infliximab, is known to be effective not only in treating abscesses but also in treating previously untreated Crohn's disease. However, this treatment is expensive and causes side effects such as fluid reabsorption or infectious complications in some patients. Current treatments for IBD include 5-aminosalicylic acid (5-ASA) drugs that block the production of prostaglandins, such as sulfasalazine, or steroid immunosuppressants. Sulfasalazine can easily cause side effects or adverse effects such as abdominal fullness, headache, rash, liver disease, leukopenia, agranulocytosis, and male infertility.

[0006] Meanwhile, Cynomorium songaricum is a fleshy, perennial, parasitic herbaceous plant of the Cynomoraceae family, native to cool, temperate, and subtropical regions, the Mediterranean, and deserts. It is known as a medicinal herb that strongly replenishes yang energy. It protects the kidneys, prevents erectile dysfunction and infertility, and forms human cell tissue. When you have numbness in the lower back and knees, lack of stamina, or suffer from constipation, eating it helps alleviate symptoms, and the stem of Cynomorium songaricum is a medicinal plant used as a tonic and to treat constipation.

[0007] Prior art related to inflammatory bowel disease includes Korean Patent No. 2252129, which discloses a "composition for preventing or treating inflammatory bowel disease comprising a paper mulberry extract," and Korean Patent No. 2453634, which discloses a "composition for preventing or treating inflammatory bowel disease comprising a sanjo-in extract." However, the "composition for preventing, improving, or treating inflammatory bowel disease comprising a sorghum extract as an active ingredient" of the present invention has not yet been disclosed.

[0008] The present invention was derived from the above needs, and the present invention provides a composition for preventing, improving, or treating inflammatory bowel disease, which contains a dextran sulfate sodium extract as an active ingredient, and more specifically, the present invention was completed by confirming that the dextran sulfate sodium extract increases the body weight decreased due to DSS in an inflammatory bowel disease animal model induced by DSS (dextran sulfate sodium), reduces the increased colon weight, and in particular, a mixture of the dextran sulfate extract and the scutellaria baicalensis extract more significantly reduces the disease activity index increased by DSS administration compared to the dextran sulfate sodium extract and the scutellaria baicalensis extract alone.

[0009] In order to solve the above problem, the present invention provides a health functional food composition for preventing or improving inflammatory bowel disease, which contains as an effective ingredient an extract of Cynomorium songaricum; or a mixture of an extract of Cynomorium songaricum and an extract of Gleditsia sinensis.

[0010] In addition, the present invention provides a pharmaceutical composition for preventing or treating inflammatory bowel disease containing a chain extract or a mixture of a chain extract and a fragment extract as an active ingredient.

[0011] In addition, the present invention provides a herbal medicine composition for preventing or treating inflammatory bowel disease containing, as an active ingredient, a schisandra chinensis extract or a mixture of a schisandra chinensis extract and a schisandra chinensis extract.

[0012] In addition, the present invention provides a feed additive for preventing or improving inflammatory bowel disease, which contains a chain extract or a mixture of a chain extract and a fragment extract as an effective ingredient.

[0013] In addition, the present invention provides a veterinary composition for preventing or treating inflammatory bowel disease containing a chain extract or a mixture of a chain extract and a fragment extract as an active ingredient.

[0014] The present invention relates to a composition for preventing, improving or treating inflammatory bowel disease, comprising a schisandra chinensis extract as an active ingredient, wherein in an animal model of inflammatory bowel disease induced by DSS, the schisandra chinensis extract increases body weight decreased due to DSS, reduces increased colon weight, and in particular, a mixture of the schisandra chinensis extract and the schisandra chinensis extract has the effect of more significantly reducing the disease activity index increased by DSS administration than the schisandra chinensis extract and the schisandra chinensis extract alone.

[0015] Figure 1 shows the effect of treating the extract of the present invention with a mouse model of inflammatory bowel disease induced by DSS (dextran sulfate sodium) to restore body weight reduced by DSS administration. ### indicates that the body weight of the negative control group was statistically significantly reduced compared to the normal group, p<0.001, and *** indicates that the body weight of the group administered with the extract of the present invention was statistically significantly increased compared to the negative control group, p<0.001.

[0016] Figure 2 shows the effect of reducing the colon weight increased by DSS administration when the extract of the present invention was treated in a DSS (dextran sulfate sodium)-induced inflammatory bowel disease mouse model. ### indicates that the colon weight of the negative control group was statistically significantly increased compared to the normal group, and p<0.001, and * indicates that the colon weight of the group administered with the extract of the dextran sulfate was statistically significantly decreased compared to the negative control group, and p<0.05.

[0017] FIG. 3 shows the effect of reducing the disease activity index increased by DSS administration when the present invention's sesame extract; or a mixture of sesame extract and sesame seed extract; was treated in an inflammatory bowel disease mouse model. ### indicates that the disease activity index of the negative control group was statistically significantly increased compared to the normal group, p<0.001. *** indicates that the disease activity index of the sesame seed extract administration group; the sesame seed extract administration group; and the mixture of sesame seed extract and sesame seed extract administration group was statistically significantly decreased compared to the negative control group, p<0.001. $$$ indicates that the disease activity index of the mixture of sesame seed extract and sesame seed extract administration group was statistically significantly decreased compared to the sesame seed extract administration group, p<0.001. &&& indicates that the disease activity index of the mixture of sesame seed extract and sesame seed extract administration group was statistically significantly decreased compared to the sesame seed extract administration group, p<0.001. ns means that there is no statistically significant difference in the disease activity index between the group administered with the extract of the chain and the group administered with the extract of the fragment.

[0018] FIG. 4 shows the effect of aryl hydrocarbon receptor (AhR) activation, which is closely related to intestinal mucosa regeneration, at various combination ratios according to the mixture treatment of the extract of the present invention and the extract of the rhizome of the rhizome. a shows that, compared to the group that was not treated with anything, the aryl hydrocarbon receptor activity of the group treated with the rhizome of the rhizome extract; the group treated with the extract of the rhizome of the rhizome; or the group treated with the mixture of the extract of the rhizome of the rhizome and the extract of the rhizome was statistically significantly increased, p<0.05; b shows that, compared to the group treated with the extract of the rhizome, the aryl hydrocarbon receptor activity of the group treated with the mixture of the extract of the rhizome and the extract of the rhizome was statistically significantly increased, p<0.05; and c shows that, compared to the group treated with the extract of the rhizome, the aryl hydrocarbon receptor activity of the group treated with the mixture of the extract of the rhizome and the extract of the rhizome was statistically significantly increased, p<0.05.

[0019] The present invention relates to a health functional food composition for preventing or improving inflammatory bowel disease, which contains as an active ingredient an extract of Cynomorium songaricum; or a mixture of an extract of Cynomorium songaricum and an extract of Gleditsia sinensis.

[0020] The above chain can be used for any part of the chain, and preferably, the chain is made of the fleshy part of the chain, but is not limited thereto.

[0021] The above carving tool can be used for any part of the pine tree, preferably a thorn of the pine tree, but is not limited thereto.

[0022] The above chain extract or fragment extract may be prepared by a method including, but not limited to, the following steps:

[0023] 1) A step of extracting by adding an extraction solvent to a chain or piece of wood;

[0024] 2) a step of filtering the extract of step 1); and

[0025] 3) A step of producing an extract by concentrating and drying the filtered extract of step 2) under reduced pressure.

[0026] The extraction solvent of the above chain extract or fragment extract is preferably independently water, a C1 to C4 lower alcohol or a mixture thereof, more preferably ethanol, and even more preferably 70% (v / v) ethanol, but is not limited thereto.

[0027] The extraction method may be any conventional method known in the art, such as filtration, hot water extraction, immersion extraction, reflux cooling extraction, and ultrasonic extraction. The extraction solvent is preferably added in an amount of 1 to 20 times the weight of the crushed or pieced material, and more preferably added in an amount of 5 to 15 times the weight of the crushed or pieced material. The extraction time is preferably 0.5 to 10 hours, and more preferably 0.5 to 5 hours, but is not limited thereto. In the above method, the reduced pressure concentration in step (3) preferably uses a vacuum reduced pressure concentrator or a vacuum rotary evaporator, but is not limited thereto. In addition, the drying is preferably performed by reduced pressure drying, vacuum drying, boiling drying, spray drying, or freeze drying, but is not limited thereto.

[0028] The above inflammatory bowel disease may be, but is not limited to, ulcerative colitis, Crohn's disease, or Behcet's disease.

[0029] The mixture of the above-mentioned chain extract and the fragment extract may be a mixture of the chain extract and the fragment extract in a weight ratio of 1 to 10:1 to 10, preferably a mixture of the chain extract and the fragment extract in a weight ratio of 1 to 5:1 to 5, most preferably a mixture of the chain extract and the fragment extract in a weight ratio of 1:1, but is not limited thereto.

[0030] The above composition is preferably prepared in any one of the following dosage forms: powder, granules, pills, tablets, capsules, candies, syrups, and beverages, but is not limited thereto.

[0031] When the health functional food composition of the present invention is used as a food additive, the effective ingredient may be added as is or used together with other foods or food ingredients, and may be used appropriately according to a conventional method. The amount of the effective ingredient may be appropriately determined depending on the purpose of use (prevention or improvement). Generally, when manufacturing a food or beverage, the composition of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, based on the raw material. However, in the case of long-term intake for the purpose of health and hygiene or health control, the amount may be below the above range, and since there is no problem in terms of safety, the effective ingredient may be used in an amount exceeding the above range. There is no particular limitation on the type of food. Examples of foods to which the extract or its fraction may be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes, and all health functional foods in the conventional sense are included.

[0032] When the composition of the present invention is used as a health beverage, it may contain various flavoring agents or natural carbohydrates as additional ingredients, as in conventional beverages. The natural carbohydrates mentioned above are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclotensin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As a sweetener, natural sweeteners such as thaumatin and stevia extract, or synthetic sweeteners such as saccharin and aspartame can be used. The proportion of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g, per 100 g of the composition of the present invention. The composition of the present invention may contain various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. In addition, the composition of the present invention may contain fruit pulp for the production of natural fruit juice, fruit juice drinks, and vegetable drinks. These components may be used independently or in mixtures. The proportion of these additives is not particularly important, but the composition of the present invention is typically selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight.

[0033] In addition, the present invention relates to a pharmaceutical composition for preventing or treating inflammatory bowel disease, which contains as an active ingredient an extract of Cynomorium songaricum; or a mixture of an extract of Cynomorium songaricum and an extract of Gleditsia sinensis.

[0034] The above inflammatory bowel disease may be, but is not limited to, ulcerative colitis, Crohn's disease, or Behcet's disease.

[0035] The composition of the present invention is preferably prepared in any one formulation selected from among capsules, powders, granules, tablets, suspensions, emulsions, syrups, and aerosols, but is not limited thereto.

[0036] The composition of the present invention may further include a pharmaceutically acceptable carrier, excipient, or diluent in addition to the above-mentioned effective ingredient, and may be in various oral or parenteral dosage forms. When formulated, it is prepared using diluents or excipients such as commonly used fillers, bulking agents, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include capsules, powders, granules, tablets, pills, etc., and these solid preparations are prepared by mixing one or more compounds with at least one excipient, such as starch, calcium carbonate, sucrose, lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, emulsions, syrups, and aerosols. In addition to commonly used simple diluents such as water and liquid paraffin, they may contain various excipients such as wetting agents, sweeteners, fragrances, and preservatives. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspending agents can be propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Suppository bases can include witepsol, macrogol, Tween 61, cacao butter, laurin butter, and glycerogelatin. For parenteral administration, it is preferable to select a method such as topical application to the skin or intraperitoneal, rectal, intravenous, intramuscular, subcutaneous, intrauterine, epidural, or intracerebrovascular injection.

[0037] The pharmaceutical composition according to the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment. The level of the effective amount may be determined based on factors including the type and severity of the patient's disease, the activity and sensitivity of the drug to the drug, the time of administration, the route of administration and excretion rate, the duration of treatment, concurrently used drugs, and other factors well known in the medical field. The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered singly or in multiple doses. It is important to take all of the above factors into consideration and administer an amount that achieves the maximum effect with the minimum amount without causing side effects, and this can be easily determined by those skilled in the art.

[0038] The dosage of the composition of the present invention varies depending on the patient's weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and disease severity, and the daily dosage is 0.01 to 2,000 mg / kg, preferably 30 to 500 mg / kg, and more preferably 50 to 300 mg / kg, based on the amount of the active ingredient, and can be administered 1 to 6 times a day. The composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modifiers.

[0039] In addition, the present invention relates to a herbal medicine composition for preventing or treating inflammatory bowel disease, which contains an extract of Cynomorium songaricum or a mixture of an extract of Cynomorium songaricum and an extract of Gleditsia sinensis as an effective ingredient.

[0040] The herbal medicine composition of the present invention means, but is not limited to, one manufactured according to a herbal medicine prescription.

[0041] In addition, the present invention relates to a feed additive for preventing or improving inflammatory bowel disease, which contains as an effective ingredient an extract of Cynomorium songaricum; or a mixture of an extract of Cynomorium songaricum and an extract of Gleditsia sinensis.

[0042] The feed additive of the present invention corresponds to supplementary feed under the Feed Management Act. The term "feed" in the present invention may mean any natural or artificial diet, meal, etc., or ingredients of the meal, which are intended for or suitable for animals to eat, ingest, and digest. The type of the feed is not particularly limited, and feed commonly used in the relevant technical field may be used. Non-limiting examples of the feed include plant feeds such as grains, roots, fruits, food processing by-products, algae, fibers, pharmaceutical by-products, oils and fats, starches, meal, or grain by-products; and animal feeds such as proteins, inorganic substances, oils and fats, mineral substances, oils and fats, single-cell proteins, zooplankton, or food. These may be used alone or in combination of two or more.

[0043] In addition, the present invention relates to a veterinary composition for preventing or treating inflammatory bowel disease, which contains as an active ingredient an extract of Cynomorium songaricum; or a mixture of an extract of Cynomorium songaricum and an extract of Gleditsia sinensis.

[0044] The veterinary composition of the present invention may further comprise suitable excipients and diluents according to conventional methods. Excipients and diluents that may be included in the veterinary composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, cetanol, stearyl alcohol, liquid paraffin, sorbitan monostearate, polysorbate 60, methylparaben, propylparaben, and mineral oil.

[0045] The veterinary composition according to the present invention may further include fillers, anticoagulants, lubricants, wetting agents, flavoring agents, emulsifiers, preservatives, etc., and the veterinary composition according to the present invention may be formulated using methods well known in the art so as to provide rapid, sustained or delayed release of the active ingredient after administration to an animal, and the formulation may be in the form of powders, granules, tablets, capsules, suspensions, emulsions, solutions, syrups, aerosols, soft or hard gelatin capsules, suppositories, sterile injectable solutions, sterile topical preparations, etc.

[0046] The effective amount of the veterinary composition according to the present invention can be appropriately selected depending on the individual animal. This may be determined based on factors including the severity of the disease or condition, the individual's age, weight, health status, or sex, sensitivity to the active ingredient of the present invention, the route of administration, the duration of administration, other compositions combined with or used concurrently with the composition, and other factors well known in the fields of physiology and veterinary medicine.

[0047]

[0048] Hereinafter, the present invention will be described in more detail using examples. These examples are intended solely to illustrate the present invention more specifically, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples.

[0049]

[0050] Example 1. Preparation of single extracts of the plant or fragments and mixtures thereof

[0051] (1) Chain extract

[0052] 1 kg of Cynomorium songaricum (the fleshy stem of Cynomorium songaricum) was placed in 10 ℓ of 70% (v / v) ethanol, refluxed for 3 hours (heating mantle), filtered and soaked with qualitative filter paper (20-25 μm), concentrated with a rotary evaporator, and then freeze-dried.

[0053]

[0054] (2) Extract of fragments

[0055] 1 kg of Gleditsia sinensis (thorns of Gleditsia sinensis) was placed in 10 ℓ of 70% (v / v) ethanol, refluxed for 3 hours (heating mantle), filtered and soaked with qualitative filter paper (20-25 μm), concentrated with a rotary evaporator, and then freeze-dried.

[0056]

[0057] (3) A mixture of chain extract and fragment extract

[0058] The above-mentioned prepared chain extract and fragment extract were mixed in a ratio of 1:1 (w / w) to prepare a mixture of chain extract and fragment extract.

[0059]

[0060] Example 2. Confirmation of the improvement effect of the extract of the chain in an animal model of inflammatory bowel disease induced by DSS.

[0061] Six-week-old male mice (C57BL / 6) were purchased from Dooyeol Biotech and acclimated for one week before use in the experiment. During the acclimation period, their general condition was observed, and only healthy mice were used in the experiment. During the test period, the experimental animals were housed in polycarbonate cages and fed mouse-specific diet ad libitum. Reverse osmosis (RO) water was provided ad libitum.

[0062] To induce inflammatory bowel disease in mice, 2.5% (w / v) dextran sodium sulfate (DSS, MP Biomedicals) drinking water was prepared. The experimental groups were divided into a normal group, a negative control group, and a group administered with 200 mg / kg of the extract of the Korean ginseng root. The samples were administered orally using the mouse gavage. The experimental groups, excluding the normal group, were fed 2.5% DSS drinking water ad libitum for 6 days, followed by a 7-day rest period and then 2.5% DSS again. The Korean ginseng root extract was administered for 16 days, starting from the 4th day after the start of DSS feeding. Body weights were measured once a day during the experimental period, and the large intestine was removed and the weight was measured during necropsy. The data obtained in the present invention were expressed as the mean ± standard error, and statistical analysis was performed using the Two-way ANOVA method and Tukey's post-hoc test for body weight changes, and the One-way ANOVA method and Dunnett's post-hoc test for colon weight changes.

[0063] As a result, as disclosed in Fig. 1, the body weight in the negative control group administered only DSS was significantly reduced compared to the normal group, and in contrast, in the group administered the chain extract of the present invention, the body weight that had been reduced by DSS administration was statistically significantly increased.

[0064] In addition, it was confirmed that the increased colon weight due to DSS administration was statistically significantly reduced by administration of the chain extract of the present invention (Fig. 2).

[0065]

[0066] Example 3. Confirmation of the improvement effect of the extract of the rhizome of the rhizome; or the mixture of the extract of the rhizome and the extract of the rhizome of the rhizome; in an animal model of inflammatory bowel disease induced by DSS.

[0067] To induce inflammatory bowel disease in mice, 2.5% (w / v) dextran sodium sulfate (DSS, MP Biomedicals) drinking water was prepared. The experimental groups were divided into the following groups: normal group; negative control group; group administered with 200 mg / kg of Ligustrum japonica extract; group administered with 200 mg / kg of Ligustrum japonica extract; and group administered with a mixture of Ligustrum japonica extract and Ligustrum japonica extract (200 mg / kg; Ligustrum japonica extract 100 mg / kg + Ligustrum japonica extract 100 mg / kg); The samples were administered orally using mouse gavage. The experimental groups, excluding the normal group, were fed 2.5% DSS drinking water ad libitum for 6 days, followed by a 7-day rest period and then 2.5% DSS again. Sample administration was administered for 16 days, starting from the 4th day after the start of DSS feeding. To evaluate the Disease Activity Index (DAI) once a day for 16 days after DSS administration, items such as weight loss, stool pattern (loose stool, diarrhea), and bleeding (hematosis, rectum) were analyzed. The DAI was evaluated by adding the corresponding values ​​of each experimental group based on the reference values ​​of each item disclosed in Table 1 below. Statistical analysis was performed using the Two-way ANOVA method and Tukey's post hoc test.

[0068] Disease Activity Index Reference Score Table Reference Score Weight Loss (%) Change in Minutes Bleeding 0<1 Normal Normal 11-5--25-10 Diarrhea-310-20--4>20 Bleeding

[0069] As a result, as disclosed in FIG. 3, the disease activity index was significantly increased in the negative control group administered only DSS compared to the normal group, and the disease activity index of the group administered the extract of the present invention; and the group administered a mixture of the extract ...

[0070]

[0071] Example 4. Confirmation of the effect of increasing the activity of the aryl hydrocarbon receptor signaling system by treatment with a mixture of the extracts of the chain and the extracts of the fragments.

[0072] In order to confirm the effect of increasing the activity of aryl hydrocarbon receptor (AhR), which is closely related to intestinal mucosa regeneration, following treatment with a mixture of the extract of the present invention and the extract of the fragments of the present invention, a cell-based analysis using a reporter gene was performed.

[0073] In detail, XRE Luciferase Reporter HEK293 Stable Cell Line (Signosis, SL-0075) was seeded at 1.5 × 10 in a 96-well plate. 4After dividing into cells / well at a concentration of 10 cells, the cells were treated with each of the following: the extract of the Korean ginseng root; the extract of the Korean ginseng root; and the mixture of the extracts of the Korean ginseng root and the Korean ginseng root; and cultured for 24 hours at 37°C in a 5% CO2 atmosphere. After removing the supernatant of the cells after culture, the cells were collected and the luciferase activity was measured using a luminometer. The fold value was calculated compared to the luciferase activity value of the untreated group to determine the activity level of the Korean ginseng root extract treatment group; the extract of the Korean ginseng root treatment group; and the mixture of the extracts of the Korean ginseng root and the Korean ginseng root treatment group. Statistical analysis was performed using the One-way ANOVA method and Dunnett's post hoc test.

[0074] As a result, as disclosed in Fig. 4, it was confirmed that the aryl hydrocarbon receptor activity was statistically significantly increased in the group treated with the mixture of the chain extract and the fragment extract compared to the group treated with the chain extract and the fragment extract alone.

Claims

1. A health functional food composition for preventing or improving inflammatory bowel disease, containing as an active ingredient an extract of Cynomorium songaricum; or a mixture of an extract of Cynomorium songaricum and an extract of Gleditsia sinensis.

2. A health functional food composition for preventing or improving inflammatory bowel disease, characterized in that in paragraph 1, the extraction solvent of the chain extract or the fragment extract is independently water, a C1-C4 lower alcohol, or a mixture thereof.

3. A health functional food composition for preventing or improving inflammatory bowel disease, characterized in that the inflammatory bowel disease in paragraph 1 is ulcerative colitis, Crohn's disease or Behcet's disease.

4. A health functional food composition characterized in that, in the first paragraph, the mixture of the extract of the chain tree and the extract of the fragments is a mixture of the extract of the chain tree and the extract of the fragments in a weight ratio of 1 to 10:1 to 10.

5. A health functional food composition for preventing or improving inflammatory bowel disease, characterized in that the composition is manufactured in any one formulation selected from powder, granules, pills, tablets, capsules, candy, syrup, and beverage in the first paragraph.

6. A pharmaceutical composition for preventing or treating inflammatory bowel disease, containing as an active ingredient an extract of Cynomorium songaricum; or a mixture of an extract of Cynomorium songaricum and an extract of Gleditsia sinensis.

7. A pharmaceutical composition for preventing or treating inflammatory bowel disease, characterized in that, in addition to the effective ingredient in paragraph 6, it further comprises a pharmaceutically acceptable carrier, excipient or diluent.

8. A pharmaceutical composition for preventing or treating inflammatory bowel disease, characterized in that the composition is prepared in any one formulation selected from among capsules, powders, granules, tablets, suspensions, emulsions, syrups, and aerosols in accordance with paragraph 6.

9. A herbal medicine composition for the prevention or treatment of inflammatory bowel disease, containing as an active ingredient an extract of Cynomorium songaricum; or a mixture of an extract of Cynomorium songaricum and an extract of Gleditsia sinensis.

10. A feed additive for preventing or improving inflammatory bowel disease, containing as an active ingredient an extract of Cynomorium songaricum; or a mixture of an extract of Cynomorium songaricum and an extract of Gleditsia sinensis.

11. A veterinary composition for the prevention or treatment of inflammatory bowel disease, containing as an active ingredient an extract of Cynomorium songaricum; or a mixture of an extract of Cynomorium songaricum and an extract of Gleditsia sinensis.

Images